Innovent Biologics (1801) H1 2025 earnings summary

Executive summary

• Achieved total revenue of RMB5,953.1 million for 2025H1, up 50.6% year-over-year, driven by strong oncology and general biomedicine sales and increased license income.

• Net profit reached RMB834.3 million, a turnaround from a prior-year loss, with Non-IFRS profit at RMB1,213.2 million and EBITDA at RMB1,412.8 million, reflecting improved operational efficiency.

• Five new products launched, expanding the portfolio to 16 marketed products, sustaining oncology leadership and driving breakthroughs in general biomedicine.

• Entered a global licensing agreement with Roche for IBI3009, receiving an $80 million upfront payment and potential milestones, supporting global R&D expansion.

• Cash reserves exceeded USD2 billion as of July 31, 2025, providing a strong financial base for future growth.

Financial highlights

• Product revenue rose 37.3% to RMB5,233.8 million; license fee income surged to RMB665.6 million, mainly from Roche.

• Gross profit margin improved to 86.8% (Non-IFRS), up 2.7pp year-over-year.

• R&D expenses decreased to RMB1,008.8 million (IFRS) and RMB903.0 million (Non-IFRS), reflecting capital efficiency.

• Selling and marketing expenses were RMB2,375.1 million, 39.9% of total revenue, down as a percentage of revenue year-over-year.

• Cash and cash equivalents stood at over RMB11 billion (USD1.5 billion) as of June 30, 2025, and USD2 billion as of July 31, 2025.

Outlook and guidance

• Anticipates further product approvals in oncology and general biomedicine by year-end 2025, including IBI112 and IBI310.

• Key growth drivers include the July launch of mazdutide and expected T2D indication approval in 2H25.

• Expects data readouts from key Phase 3 trials for mazdutide and other assets in 2H25 and early 2026.

• Plans to accelerate global expansion, with ongoing registration and commercialization in international markets.

• Three-year plan targets 20 commercial products and RMB20 billion product revenue by 2027.